Roundview Capital LLC cut its holdings in Celcuity, Inc. (NASDAQ:CELC – Free Report) by 59.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,778 shares of the company’s stock after selling 4,079 shares during the quarter. Roundview Capital LLC’s holdings in Celcuity were worth $277,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the business. EverSource Wealth Advisors LLC grew its position in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after acquiring an additional 319 shares during the last quarter. Ogorek Anthony Joseph NY ADV bought a new stake in Celcuity during the 3rd quarter worth $27,000. US Bancorp DE grew its position in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the last quarter. NBC Securities Inc. bought a new stake in Celcuity during the 4th quarter worth $99,000. Finally, Everhart Financial Group Inc. bought a new stake in Celcuity during the 4th quarter worth $209,000. 63.33% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Celcuity
In other Celcuity news, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the transaction, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 37,000 shares of company stock worth $5,111,950. 13.33% of the stock is owned by company insiders.
Analyst Ratings Changes
Get Our Latest Stock Analysis on CELC
Celcuity Stock Down 2.3%
Shares of NASDAQ:CELC opened at $130.91 on Friday. The stock has a market cap of $6.38 billion, a price-to-earnings ratio of -33.57 and a beta of 0.09. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 12-month low of $10.50 and a 12-month high of $151.02. The business’s 50 day moving average is $122.68 and its 200 day moving average is $110.78.
Celcuity (NASDAQ:CELC – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, sell-side analysts forecast that Celcuity, Inc. will post -3.96 earnings per share for the current fiscal year.
About Celcuity
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Read More
- Five stocks we like better than Celcuity
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC – Free Report).
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
